All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Equity

BlackRock backs UK life sciences firm in latest PE round

biotech_microscope_drug_production_adobe_575x375_oct13

BlackRock, the US asset manager, has taken part in a $75m Series 'C' financing for Immunocore, a UK life sciences company that works in developing treatments that use the body’s T-cell receptors to fight cancer and other diseases.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree